US Senate gives go ahead to device user fees
This article was originally published in Clinica
Executive Summary
The US FDA yesterday (October 17) received the go-ahead for charging fees for medical device companies that use its approvals system. The Senate voted unanimously on October 17 in favour of the Medical Device Amendment Bill. It was an amended version of the bill that the House had put forward, as HR 3580, a week earlier (see Clinica No 1028, p 1). The House passed the amended bill in mid-week.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.